Hotchkis & Wiley Capital Management’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $199M | Buy |
|
|||||
|
2025
Q2 | $175M | Sell |
|
|||||
|
2025
Q1 | $180M | Sell |
|
|||||
|
2024
Q4 | $157M | Buy |
|
|||||
|
2024
Q3 | $145M | Buy |
|
|||||
|
2024
Q2 | $104M | Sell |
|
|||||
|
2024
Q1 | $117M | Sell |
|
|||||
|
2023
Q4 | $102M | Sell |
|
|||||
|
2023
Q3 | $103M | Sell |
|
|||||
|
2023
Q2 | $102M | Sell |
|
|||||
|
2023
Q1 | $103M | Sell |
|
|||||
|
2022
Q4 | $103M | Sell |
|
|||||
|
2022
Q3 | $88.2M | Sell |
|
|||||
|
2022
Q2 | $198M | Sell |
|
|||||
|
2022
Q1 | $360M | Sell |
|
|||||
|
2021
Q4 | $380M | Sell |
|
|||||
|
2021
Q3 | $349M | Sell |
|
|||||
|
2021
Q2 | $380M | Sell |
|
|||||
|
2021
Q1 | $363M | Sell |
|
|||||
|
2020
Q4 | $381M | Buy |
|
|||||
|
2020
Q3 | $279M | Buy |
|
|||||
|
2020
Q2 | $295M | Sell |
|
|||||
|
2020
Q1 | $280M | Buy |
|
|||||
|
2019
Q4 | $346M | Buy |
|
|||||
|
2019
Q3 | $284M | Sell |
|
|||||
|
2019
Q2 | $307M | Buy |
|
|||||
|
2019
Q1 | $301M | Sell |
|
|||||
|
2018
Q4 | $281M | Sell |
|
|||||
|
2018
Q3 | $338M | Buy |
|
|||||
|
2018
Q2 | $337M | Sell |
|
|||||
|
2018
Q1 | $334M | Buy |
|
|||||
|
2017
Q4 | $298M | Sell |
|
|||||
|
2017
Q3 | $342M | Buy |
|
|||||
|
2017
Q2 | $338M | Buy |
|
|||||
|
2017
Q1 | $317M | Sell |
|
|||||
|
2016
Q4 | $301M | Sell |
|
|||||
|
2016
Q3 | $352M | Sell |
|
|||||
|
2016
Q2 | $366M | Sell |
|
|||||
|
2016
Q1 | $362M | Sell |
|
|||||
|
2015
Q4 | $488M | Sell |
|
|||||
|
2015
Q3 | $477M | Buy |
|
|||||
|
2015
Q2 | $484M | Sell |
|
|||||
|
2015
Q1 | $568M | Buy |
|
|||||
|
2014
Q4 | $522M | Buy |
|
|||||
|
2014
Q3 | $497M | Buy |
|
|||||
|
2014
Q2 | $265M | Buy |
|
|||||
|
2014
Q1 | $1.97M | Buy |
|